secwatch.observer — SEC 8-K summary
======================================

Issuer:     AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK:        0001439222
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001439222-25-000087
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Agios Q2 2025 net loss $112M; PYRUKYND revenue $12.5M; PDUFA Sept 7 for thalassemia
--------------------------------------------------------------------------------

- Net loss $112.0M vs $96.1M YoY; PYRUKYND net revenue $12.5M, up from $8.6M in Q2 2024.
- Cash and marketable securities $1.3B; expects to fund potential thalassemia and SCD launches.
- FDA PDUFA goal date for PYRUKYND sNDA in thalassemia is Sept 7, 2025; launch prep underway.
- RISE UP Phase 3 topline for mitapivat in sickle cell disease on track by year-end 2025.
- Dosed first patient in tebapivat Phase 2 for SCD; IND clearance for AG-236 siRNA for PV.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/0001439222-25-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439222/000143922225000087/agio-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001439222-25-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer